This is an archive of papers published by the staff and faculty of Fox Chase Cancer Center. For questions about content, please contact Talbot Research Library
Last updated on
Witzig TE , Molina A , Gordon LI , Emmanouilides C , Schilder RJ , Flinn IW , Darif M , Macklis R , Vo K , Wiseman GA
Long-term responses in patients with recurring or refractory B-Ccll non-hodgkin lymphoma treated with yttrium 90 ibritumomab tiuxetan
Cancer. 2007 May;109(9) :1804-1810
AbstractBACKGROUND. Radioimmunotherapy with radiolabeled monoclonal antibodies to CD20 produces a high response rate in patients with recurring non-Hodgkin lymphoma (NHL), but the durability of those remissions is not well defined. METHODS. Data on patients with recurring NHL treated with yttrium Y 90 ibritumomab tiuxetan in 4 clinical trials were reviewed to identify patients with a long-term response, defined as a time to progression of 12 months or longer. RESULTS. Long-term responses were seen in 37% (78/211) of patients. At a median follow-up of 53.5 months (range, 12.7-88.9) the median duration of response was 28.1 months and the median time to progression was 29.3 months. A third of these patients had been treated with at least 3 previous therapies, and 37% of them had not responded to their last therapy. The findings in patients with follicular lymphoma (n = 59) were similar to those in the overall population of long-term responders. The estimated overall survival at 5 years was 53% for all patients treated with Y-90 ibritumomab tiuxetan and 81% for long-term responders. CONCLUSIONS. A single dose of Y-90 ibritumomab tiuxetan can produce durable responses and prolonged overall survival in a substantial number of patients in whom previous therapies have failed.